↓ Skip to main content

Emerging therapy for endometriosis

Overview of attention for article published in Expert Opinion on Emerging Drugs, June 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
2 X users
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Emerging therapy for endometriosis
Published in
Expert Opinion on Emerging Drugs, June 2015
DOI 10.1517/14728214.2015.1051966
Pubmed ID
Authors

Sarah F Lindsay, Danielle E Luciano, Anthony A Luciano

Abstract

Endometriosis is a chronic disease manifested by pain and infertility due to ectopic implantation of endometrial glands and stroma causing inflammation. Treatment of endometriosis utilizes a significant amount of health-care resources and requires chronic therapy. Management involves a combination of surgical and medical interventions and requires long-term treatment to avoid repeated surgeries. Areas covered: Whereas medical therapies exist for management of endometriosis-related pain, each class has its limitations including side effects, cost, and known duration of relief of symptoms. Development of effective, well-tolerated medical therapies that are appropriate for long-term use is crucial to provide adequate treatment for this chronic disease. This review discusses the various medical therapies available, their limitations, and emerging therapies being developed to address many of these concerns. Expert opinion: The authors recommend chronic suppressive therapy for management of endometriosis symptoms, particularly in the postoperative setting. Empiric treatment is appropriate for those patients without evidence of severe disease. Currently available option may not be effective for nor tolerated by all patients. Newer compounds, including gonadotropin-releasing antagonists and aromatase inhibitors combined with hormonal contraceptives, offer possible alternatives to currently available therapies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 23%
Researcher 5 14%
Student > Master 4 11%
Other 3 9%
Student > Doctoral Student 3 9%
Other 3 9%
Unknown 9 26%
Readers by discipline Count As %
Medicine and Dentistry 7 20%
Agricultural and Biological Sciences 4 11%
Biochemistry, Genetics and Molecular Biology 3 9%
Nursing and Health Professions 2 6%
Psychology 2 6%
Other 5 14%
Unknown 12 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2021.
All research outputs
#6,426,255
of 22,830,751 outputs
Outputs from Expert Opinion on Emerging Drugs
#138
of 493 outputs
Outputs of similar age
#76,099
of 266,043 outputs
Outputs of similar age from Expert Opinion on Emerging Drugs
#7
of 19 outputs
Altmetric has tracked 22,830,751 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 493 research outputs from this source. They receive a mean Attention Score of 4.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,043 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.